Practical aspects of application lacosamide in patients with epilepsy Review article
Article Sidebar
Published:
Jun 20, 2022
Keywords:
lacosamide, epilepsy, treatment
Main Article Content
Abstract
Lacosamide is a third generation antiepileptic drug approved for the treatment of focal onset with or without evaluation to bilateral seizures as monotherapy and adjunctive therapy. Generally, it is well tolerated and has low potential for interactions with other drugs including contraceptive pills. Lacosamide is valuable treatment option for patient with newly diagnosed epilepsy.
Article Details
How to Cite
Kopka , M. (2022). Practical aspects of application lacosamide in patients with epilepsy. Medycyna Faktow (J EBM), 15(2(55), 190-194. https://doi.org/10.24292/01.MF.0222.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003; 349: 1257-66.
2. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069-77.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342: 314-9.
4. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11: 792-802.
5. Errington AC, Stöhr T, Heers C et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73(1): 157-69.
6. Thomas D, Horstmann R, Scharfenecker U et al. Lacosamide has low potential for drug-drug-interaction. Poster presented at: The American Society of Consultant Pharmacists 38th Annual Meeting, Philadelphia, PA, November 14–17, 2007.
7. Cawello W, Kropeit D, Schiltmeyer B et al. Food does not affect the pharmacokinetics of SPM 927 (Abstract). Epilepsia. 2004; 45(suppl 7): 307.
8. Horstmann R, Bonn R, Cawello W et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM927 (Abstract). Epilepsia. 2002; 43(suppl 7): 188.
9. Kropeit D, Scharfenecker U, Schiltmeyer B et al. Lacosamide has low potential for drug-drug interaction (Abstract 851). J Pain. 2006; 7: S63.
10. Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48: 1308-17.
11. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009; 50(3): 443-53.
12. Chung S, Sperling MR, Biton V et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010; 51(6): 958-67.
13. Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010; 24(12): 1041-54.
14. Sake JK, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010; 24(12): 1055-68.
15. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology. 2008; 70: 54-65.
16. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 2001; 47: 17-25.
17. Husain A, Chung S, Faught E et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia. 2012; 53: 521-8.
18. Rosenfeld W, Fountain NB, Kaubrys G et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a longterm open-label extension trial of up to 8 years. Epilepsy Behav. 2014; 41: 164-70.
19. Rosenow F, Kelemen A, Ben-Menachem E et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2016; 133: 136-44.
20. Runge U, Arnold S, Brandt C et al. A noninterventional study evaluating the eff ectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study. Epilepsia. 2015; 56: 1921-30.
21. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 2012; 23: 298-304.
22. Baulac MJ, Rosenow F, Toledo M et al. Efficacy and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly-diagnosed epilepsy: a phase 3 randomised double-blind non-inferiority trial. Lancet Neurol. 2016; 16: 43-54.
23. Wechsler RT, Li G, French J et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014; 55: 1088-98.
24. Del Bianco C, Placidi F, Liguori C et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy Behav. 2019; 94: 178-82.
25. Lattanzi S, Cagnetti C, Foschi N et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015; 27: 71-4.
26. Wilner AN, Sharma BK, Soucy A et al. Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010. Epilepsy Behav. 2014; 32: 15-20.
27. Casciato S, Quarato PP, Gialluisi A et al. Lacosamide as first add-on or conversion monotherapy: A retrospective real-life study. Epilepsy Behav. 2021; 122: 108-28.
28. Villanueva V, Giráldez BG, Toledo M et al. Lacosamide monotherapy in clinical practice: a retrospective chart review. Acta Neurol Scand. 2018; 138(3): 186-94.
29. Lachuer C, Corny J, Bézie Y et al. Complete atrioventricular block in an elderly patient treated with low-dose lacosamide. Cardiovasc Toxicol.
2018; 18(6): 579-82.
30. Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61: 1-48.
31. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 1996; 313: 1169-74.
32. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381. http://doi.org/10.3389/fphar.2021.694381.
33. Rejdak K, Rola R, Mazurkiewicz-Bełdzińska M et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2020; 16(3): 129-44.
34. https://indeks.mp.pl/leki/desc.php?id=17040 (access: 11.04.2022).
35. Sander JW. The use of antiepileptic drugs – principles and practice. Epilepsia. 2004; 45(suppl 6): 28-34.
2. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069-77.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342: 314-9.
4. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11: 792-802.
5. Errington AC, Stöhr T, Heers C et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73(1): 157-69.
6. Thomas D, Horstmann R, Scharfenecker U et al. Lacosamide has low potential for drug-drug-interaction. Poster presented at: The American Society of Consultant Pharmacists 38th Annual Meeting, Philadelphia, PA, November 14–17, 2007.
7. Cawello W, Kropeit D, Schiltmeyer B et al. Food does not affect the pharmacokinetics of SPM 927 (Abstract). Epilepsia. 2004; 45(suppl 7): 307.
8. Horstmann R, Bonn R, Cawello W et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM927 (Abstract). Epilepsia. 2002; 43(suppl 7): 188.
9. Kropeit D, Scharfenecker U, Schiltmeyer B et al. Lacosamide has low potential for drug-drug interaction (Abstract 851). J Pain. 2006; 7: S63.
10. Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48: 1308-17.
11. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009; 50(3): 443-53.
12. Chung S, Sperling MR, Biton V et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010; 51(6): 958-67.
13. Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010; 24(12): 1041-54.
14. Sake JK, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010; 24(12): 1055-68.
15. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology. 2008; 70: 54-65.
16. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 2001; 47: 17-25.
17. Husain A, Chung S, Faught E et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia. 2012; 53: 521-8.
18. Rosenfeld W, Fountain NB, Kaubrys G et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a longterm open-label extension trial of up to 8 years. Epilepsy Behav. 2014; 41: 164-70.
19. Rosenow F, Kelemen A, Ben-Menachem E et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2016; 133: 136-44.
20. Runge U, Arnold S, Brandt C et al. A noninterventional study evaluating the eff ectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study. Epilepsia. 2015; 56: 1921-30.
21. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 2012; 23: 298-304.
22. Baulac MJ, Rosenow F, Toledo M et al. Efficacy and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly-diagnosed epilepsy: a phase 3 randomised double-blind non-inferiority trial. Lancet Neurol. 2016; 16: 43-54.
23. Wechsler RT, Li G, French J et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014; 55: 1088-98.
24. Del Bianco C, Placidi F, Liguori C et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy Behav. 2019; 94: 178-82.
25. Lattanzi S, Cagnetti C, Foschi N et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015; 27: 71-4.
26. Wilner AN, Sharma BK, Soucy A et al. Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010. Epilepsy Behav. 2014; 32: 15-20.
27. Casciato S, Quarato PP, Gialluisi A et al. Lacosamide as first add-on or conversion monotherapy: A retrospective real-life study. Epilepsy Behav. 2021; 122: 108-28.
28. Villanueva V, Giráldez BG, Toledo M et al. Lacosamide monotherapy in clinical practice: a retrospective chart review. Acta Neurol Scand. 2018; 138(3): 186-94.
29. Lachuer C, Corny J, Bézie Y et al. Complete atrioventricular block in an elderly patient treated with low-dose lacosamide. Cardiovasc Toxicol.
2018; 18(6): 579-82.
30. Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61: 1-48.
31. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 1996; 313: 1169-74.
32. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381. http://doi.org/10.3389/fphar.2021.694381.
33. Rejdak K, Rola R, Mazurkiewicz-Bełdzińska M et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2020; 16(3): 129-44.
34. https://indeks.mp.pl/leki/desc.php?id=17040 (access: 11.04.2022).
35. Sander JW. The use of antiepileptic drugs – principles and practice. Epilepsia. 2004; 45(suppl 6): 28-34.